



# UNITED STATES PATENT AND TRADEMARK OFFICE

1A  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,381	05/16/2005	Douglas Wade Beight	X16014	3880
25885	7590	11/15/2007	EXAMINER	
ELI LILLY & COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, IN 46206-6288			RAHMANI, NILOOFAR	
		ART UNIT		PAPER NUMBER
		1625		
		NOTIFICATION DATE	DELIVERY MODE	
		11/15/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

[patents@lilly.com](mailto:patents@lilly.com)

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/535,381	BEIGHT ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Niloofer Rahmani	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 11 September 2007.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 14-16 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 14-16 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application |
|  | 6) <input type="checkbox"/> Other: _____                          |

**DETAILED ACTION**

1. Claims 14-16 are pending in the instant application and claims 1-13 are cancelled.

***Priority***

2. This application is filed on 05/16/2005, which is a 371 of PCT/US03/35969, filed on 11/24/2003, which claims benefit of 60/429982, filed on 11/27/2002.

3. The rejection of claims 1-,9, and 11 under 112, second paragraph is withdrawn due to the applicants amendment on paper dated 09/11/2007.

4. The rejection of the new claim 16 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is maintained for reason of record. Applicants argue that the new claim 16 overcomes the rejection is acknowledge. However, it is not seen where the written description and enablement is provided by the instant application. The examiner maintains the rejection since the treatment of breast and prostate cancer does not have any support in the instant application. There is no link between the inhibition of TGF-B Type I receptor kinase and real world treatment of these cancer. Therefore, the rejection is maintained for the reason of record.

5. The rejection of the new claims 14-16 under 35 U.S.C. 103(a) over sawyer et al., WO 2002/094,833 is maintained for reason of record.

Applicants argue that the claims 1-3,9, and11 have been cancelled to obviate this rejection. However, Sawyer et al. still teaches analog compounds, pharmaceutical composition and utility as the instant claims. Because one having skill in the art would be motivated to modify the compounds of the reference to obtain the instant compounds, i.e., Quinoline and Isoquinoline are positional isomer. The claims would have been obvious because the substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention.

6. The rejection of the new claims 14-16 under Ovious Double Patenting over Beight et al., US 206/0040983, Sawyer et al., US 2006/0079680, and Sawyer et al., US7,087,626 is maintained for reason of record. Applicants argue that the claims 1-3,9, and11 have been cancelled to obviate this rejection. However, Beight et al, Sawyer et al. still teaches analog compounds, pharmaceutical composition and utility as the instant claims. Because one having skill in the art would be motivated to modify the compounds of the reference to obtain the instant compounds, i.e., Quinoline and Isoquinoline are positional isomer. The claims would have been obvious because the substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention.

**THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on

Art Unit: 1625

access to the Private PAIR system, contact the Electronic Business Center  
(EBC) at 866-217-9197 (toll-free).

NILOOFAR RAHMANI

11/07 /2007

Nh



MARGARET D. SEAMAN

PRIMARY EXAMINER

GROUP 1625